Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance

Oncogene

Volumn 35, Issue 8, 2016, Pages 990-1002

  Khongkow, P ^a   Gomes, A R ^a   Gong, C ^a,b   Man, E P S ^b   Tsang, J W H ^b   Zhao, F ^a,b   Monteiro, L J ^a,d   Coombes, R C ^a   Medema, R H ^c   Khoo, U S ^b   Lam, E W F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSIDAD DE LOS ANDES   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALPHA TUBULIN; BETA TUBULIN; CYCLIN B1; KIF20A PROTEIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; KIF20A PROTEIN, HUMAN; KINESIN;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL CYCLE PROGRESSION; CELL SURVIVAL; CELL VIABILITY; CHROMOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG TARGETING; GENE SILENCING; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MCF 7 CELL LINE; MITOSIS; MITOSIS SPINDLE; MITOTIC CATASTROPHE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; SENESCENCE; ANIMAL; BREAST NEOPLASMS; CELL AGING; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY; SPINDLE APPARATUS; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL AGING; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINESIN; MICE; MITOSIS; PACLITAXEL; PROMOTER REGIONS, GENETIC; SPINDLE APPARATUS; TUMOR CELLS, CULTURED;

EID: 84959457127     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.152     Document Type: Article

References (41)

1. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008; 34: 378-390.
2. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007; 12: 271-280.
3. Misiukiewicz K, Gupta V, Bakst R, Posner M. Taxanes in cancer of the head and neck. Anticancer Drugs 2014; 25: 561-570.
4. Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracyclineand taxane-refractory metastatic breast cancer. Semin Oncol 2008; 35: S31-S38 quiz S40.
5. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608: 1-22.
6. Rohena CC, Mooberry SL. Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities. Nat Prod Rep 2014; 31: 335-355.
7. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10: 51-57.
8. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-120.
9. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011; 12: 385-392.
10. Lam EW, Brosens JJ, Gomes AR, Koo CY. Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer 2013; 13: 482-495.
11. Khongkow P, Karunarathna U, Khongkow M, Gong C, Gomes AR, Yague E, et al. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene 2014; 33: 4144-4155.
12. Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D, et al. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene 2013; 32: 4634-4645.
13. Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, et al. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010; 8: 24-34.
14. Verhey KJ, Hammond JW. Traffic control: regulation of kinesin motors. Nat Rev Mol Cell Biol 2009; 10: 765-777.
15. Hirokawa N, Noda Y, Okada Y. Kinesin and dynein superfamily proteins in organelle transport and cell division. Curr Opin Cell Biol 1998; 10: 60-73.
16. Hirokawa N, Noda Y, Tanaka Y, Niwa S. Kinesin superfamily motor proteins and intracellular transport. Nat Rev Mol Cell Biol 2009; 10: 682-696.
17. Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. Nature 2000; 407: 41-47.
18. Myatt SS, Kongsema M, Man CW, Kelly DJ, Gomes AR, Khongkow P, et al. SUMOylation inhibits FOXM1 activity and delays mitotic transition. Oncogene 2014; 33: 4316-4329.
19. Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 2005; 65: 5181-5189.
20. Kitagawa M, Fung SY, Hameed UF, Goto H, Inagaki M, Lee SH. Cdk1 coordinates timely activation of MKlp2 kinesin with relocation of the chromosome passenger complex for cytokinesis. Cell Rep 2014; 7: 166-179.
21. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7: 847-859.
22. Landt SG, Marinov GK, Kundaje A, Kheradpour P, Pauli F, Batzoglou S, et al. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res 2012; 22: 1813-1831.
23. Schuller U, Zhao Q, Godinho SA, Heine VM, Medema RH, Pellman D, et al. Forkhead transcription factor FoxM1 regulates mitotic entry and prevents spindle defects in cerebellar granule neuron precursors. Mol Cell Biol 2007; 27: 8259-8270.
24. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-731.
25. Kline-Smith SL, Walczak CE. Mitotic spindle assembly and chromosome segregation: refocusing on microtubule dynamics. Mol Cell 2004; 15: 317-327.
26. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003; 278: 49795-49805.
27. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 2006; 66: 212-220.
28. Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, et al. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol 2009; 35: 57-68.
29. Karadedou CT, Gomes AR, Chen J, Petkovic M, Ho KK, Zwolinska AK, et al. FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene 2012; 31: 1845-1858.
30. Laoukili J, Kooistra MR, Bras A, Kauw J, Kerkhoven RM, Morrison A, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 2005; 7: 126-136.
31. Sawin KE, Endow SA. Meiosis, mitosis and microtubule motors. Bioessays 1993; 15: 399-407.
32. Neef R, Gruneberg U, Barr FA. Assay and functional properties of Rabkinesin-6/Rab6-KIFL/MKlp2 in cytokinesis. Methods Enzymol 2005; 403: 618-628.
33. Nguyen PA, Groen AC, Loose M, Ishihara K, Wuhr M, Field CM, et al. Spatial organization of cytokinesis signaling reconstituted in a cell-free system. Science 2014; 346: 244-247.
34. Nitta M, Kobayashi O, Honda S, Hirota T, Kuninaka S, Marumoto T, et al. Spindle checkpoint function is required for mitotic catastrophe induced by DNAdamaging agents. Oncogene 2004; 23: 6548-6558.
35. Khongkow M, Olmos Y, Gong C, Gomes AR, Monteiro LJ, Yague E, et al. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis 2013; 34: 1476-1486.
36. Kwok JM, Myatt SS, Marson CM, Coombes RC, Constantinidou D, Lam EW. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression. Mol Cancer Ther 2008; 7: 2022-2032.
37. Okuyama R, Aruga A, Hatori T, Takeda K, Yamamoto M. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Oncoimmunology 2013; 2: e27010.
38. Tcherniuk S, Skoufias DA, Labriere C, Rath O, Gueritte F, Guillou C, et al. Relocation of Aurora B and survivin from centromeres to the central spindle impaired by a kinesin-specific MKLP-2 inhibitor. Angew Chem Int Ed Engl 2010; 49: 8228-8231.
39. Liu J, Wang QC, Cui XS, Wang ZB, Kim NH, Sun SC. MKlp2 inhibitor paprotrain affects polar body extrusion during mouse oocyte maturation. Reprod Biol Endocrinol 2013; 11: 117.
40. Exertier P, Javerzat S, Wang B, Franco M, Herbert J, Platonova N, et al. Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5. Oncotarget 2013; 4: 2302-2316.
41. Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, et al. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PloS One 2010; 5: e12293.